Ypsomed Group
http://www.ypsomed.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ypsomed Group
Deal Watch: Revance To Go Private In Crown Laboratories Buyout
Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.
Gilead Partners With Tentarix In Platform Discovery Deal
Deal Snapshot: Gilead will collaborate with the start-up on the discovery and development of first-in-class targeted, multifunctional, conditional therapeutics.
FDA Clears Abbott’s Modified CGM For Automated Insulin Delivery Integration, Label Expansion
Abbott announced today it plans to integrate its FDA-cleared modified CGMs with insulin pump makers, including Tandem and Insulet, likely later this year.
Market Intel: Rivalry Among Insulin Pump Makers Heats Up With Expected Launches In 2021
The global insulin pump market is expected to see double-digit growth, reaching $5.1bn in 2024, with product launches expected by Medtronic, Insulet, Tandem and smaller players in 2021.
Company Information
- Industry
-
Medical Devices
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
-
- Ypsotec Ag, DiaExpert GmbH, Florian Muller GmbH, Ypsomed, Ypsomed Distribution AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice